中文摘要：

目的：通过回顾性分析中国北方15个血液病研究中心的586例伴有t（8;21）的急性髓系白血病（AML）患者临床资料,总结其在外周血、免疫分型、融合基因、细胞遗传学改变等的临床特点。方法：用COX回归进行预后因素的单因素和多因素分析,探究能够影响t（8;21）AML患者预后生存的因素。结果：t（8;21）AML患者的免疫分型中以HLA-DR＋、CD117＋、CD34＋、MPO＋、CD38＋、CDl3＋、CD33＋多见（〉95%）,部分患者伴有CD19＋和CD56＋;最常见的伴随基因突变为C-KIT突变（37.8%）;除t（8;21）异位外,最常见的伴随染色体异常为性染色体缺失（38.9%）;单因素分析显示,初诊时WBC≤3.5×10^9/L、不伴随C-KIT突变、做过HSCT的成人t（8;21）AML患者在OS、PFS上均有明显优势（P〈0.05）,不伴有髓外浸润、CD19＋患者仅在OS上具有优势;多因素分析显示,WBC≤3.5×10^9/L的患者在OS、PFS上均优于WBC〉3.5×10^9/L的患者（P〈0.05）。结论：中国的t（8;21）AML患者临床特征与报道的国外人群基本相似,WBC≤3.5×10^9/L是t（8;21）AML的预后良好因素,C-KIT突变是t（8;21）AML的预后不良因素。

英文摘要：

Objective： To summarize the clinical characteristics of peripheral blood,immune phenotypes,fusion genes and cytogenetics of patients with t（ 8; 21） acute myeloid leukemia（ AML） through the retrospective analysis of 586 patients with t（ 8; 21） AML from 15 blood disease research centers in Northern area of China. Methods： The factors affecting prognosis of patients with t（ 8; 21） AML were investigated by using univariate and multivariate COX regression. Results： The immune type of t（ 8; 21） AML patients was mainly with HLA-DR＋,CD117＋,CD34 ＋,MPO＋,CD38＋,CD13＋ and CD33＋（ 95%）,part of them with CD19 ＋ and CD56 ＋; the most common accompanied mutation of t（ 8; 21） AML patients was C-KIT mutation（ 37. 8%）; in addition to t（ 8; 21） ectopic,the most common chromosomal abnormality was sex chromosome deletions（ 38. 9%）. The univariate analysis revealed a significant survival superiority of OS and PFS in t（ 8; 21） AML patients of WBC≤3. 5 × 109/L without C-KIT mutation,the newly diagnosed ones achieved HSCT（ P〈0. 05）,only survival superiority on OS in t（ 8; 21） AML patients with extramedullary infiltration and CD19 positive; the results of multivariate analysis showed a significant survival superiority on OS and PFS in t（ 8; 21） AML patients with WBC≤3. 5 × 10^9/L（ P〈0. 05）. Conclusion： The clinical features of t（ 8; 21） AML patients in China are similar to those in other countries,WBC≤3. 5 × 109/L is a good prognostic factor while the C-KIT mutation is a poor one in t（ 8; 21） AML patients.